login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
AMNEAL PHARMACEUTICALS INC (AMRX) Stock News
USA
- NASDAQ:AMRX -
US03168L1052
-
Common Stock
11.64
USD
+0.12 (+1.04%)
Last: 11/14/2025, 5:40:40 PM
11.64
USD
0 (0%)
After Hours:
11/14/2025, 5:40:40 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
AMRX Latest News, Press Relases and Analysis
All
Press Releases
15 days ago - By: Chartmill
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Q3 2025 Earnings: EPS Beats Estimates, Stock Surges on Raised Guidance
10 hours ago - By: Zacks Investment Research
- Mentions:
TEVA
ANIP
VTRS
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
a day ago - By: Amneal Pharmaceuticals LLC
Amneal Receives U.S. FDA Approval for Iohexol Injection
a day ago - By: Amneal Pharmaceuticals LLC
Amneal Receives U.S. FDA Approval for Iohexol Injection
10 days ago - By: Zacks Investment Research
Implied Volatility Surging for Amneal Pharmaceuticals Stock Options
15 days ago - By: Zacks Investment Research
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
16 days ago - By: Benzinga
- Mentions:
IR
CDP
ENTG
BUD
...
Earnings Scheduled For October 30, 2025
16 days ago - By: Amneal Pharmaceuticals LLC
Amneal Reports Third Quarter 2025 Financial Results
16 days ago - By: Amneal Pharmaceuticals LLC
Amneal Reports Third Quarter 2025 Financial Results
16 days ago - By: Amneal Pharmaceuticals LLC
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
18 days ago - By: Amneal Pharmaceuticals LLC
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
18 days ago - By: Amneal Pharmaceuticals LLC
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
22 days ago - By: Zacks Investment Research
- Mentions:
UTHR
Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for
a month ago - By: Benzinga
- Mentions:
AMPH
TEVA
RDY
VTRS
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs
a month ago - By: Kashiv BioSciences, LLC and Amneal Pharmaceuticals, Inc. and Alvotech and Advanz Pharma
- Mentions:
ALVO
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
a month ago - By: Zacks Investment Research
- Mentions:
ANIX
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
2 months ago - By: Amneal Pharmaceuticals LLC
Amneal to Report Third Quarter 2025 Results on October 30, 2025
2 months ago - By: Amneal Pharmaceuticals LLC
Amneal to Report Third Quarter 2025 Results on October 30, 2025
2 months ago - By: Amneal Pharmaceuticals LLC
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
2 months ago - By: Amneal Pharmaceuticals LLC
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
2 months ago - By: Stocktwits
- Mentions:
AGN
Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops
2 months ago - By: Amneal Pharmaceuticals LLC
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
2 months ago - By: Amneal Pharmaceuticals LLC
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
2 months ago - By: Amneal Pharmaceuticals LLC
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
2 months ago - By: Amneal Pharmaceuticals LLC
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
2 months ago - By: Amneal Pharmaceuticals LLC
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
Please enable JavaScript to continue using this application.